On the stock market since 1987, it operates in the world of health and science. It has 73 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 9% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades below its recent peak — about 14% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 14% a year on average.
Sales run at $27.6M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 18 buys and 2 sells. Management buying with its own money is usually read as a good sign.
A loss of $1.0M against $27.6M in annual sales.
On our five-subject report card, ICCC sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ICCC is a high-risk stock — not yet profitable, and its future rides on its product catching on.